---
title: "MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286965125.md"
description: "Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls."
datetime: "2026-05-19T20:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286965125.md)
  - [en](https://longbridge.com/en/news/286965125.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286965125.md)
---

# MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Mangoceuticals, Inc. reported first-quarter 2026 results with revenue of $67.9K, down from $109.3K a year earlier, and a net loss attributable to common stockholders of $3.7M; basic and diluted loss per share was $(0.22) for the quarter — a narrower loss than the prior year period. — 10-Q Summary

**Financial Highlights**

-   Revenue was $67.9K for Q1 2026, compared with $109.3K in Q1 2025 (YoY change (37.9%)).
-   Net income: Net loss attributable to Mangoceuticals, Inc. common stockholders was $(3,697,150) for Q1 2026 vs. $(5,133,391) in Q1 2025.
-   Diluted EPS: Basic and diluted loss per share was $(0.22) for Q1 2026 vs. $(1.12) for Q1 2025.

**Business Highlights**

-   Revenue decline reflected the company prioritizing in-house website development and targeted testosterone replacement therapy (TRT) testing prior to full launch.
-   Fulfillment strategy shifted toward increased use of third-party providers, reducing related-party pharmacy spend; Epiq Scripts remains the primary compounder.
-   Continued commercialization of Mango, Grow, Mojo, Slim RDTs and PRIME (oral TRT) with a website relaunch in progress.
-   Operational progress includes completion of the majority of Phase II respiratory studies in 2025 and preparation for Dermytol skin product commercialization planned for Q3 2026.
-   Cost controls included reduced marketing and investor-relations spend and lower G&A and consulting costs, while stock-based compensation increased to conserve cash.

Original SEC Filing: MANGOCEUTICALS, INC. \[ MGRX \] - 10-Q - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MGRX.US](https://longbridge.com/en/quote/MGRX.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)